A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

NCT03329508 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

544

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease
Early Parkinson's Disease

Interventions

DRUG: P2B001 0.6/0.75 mg
DRUG: Rasagiline 0.75 mg
DRUG: Pramipexole 0.6 mg
DRUG: Marketed Pramipexole ER

Sponsor

Pharma Two B Ltd.